Transferrin Test

If you have ever been told your iron is "fine" based on a single ferritin or hemoglobin number, you may be getting an incomplete picture. Transferrin is the protein your liver builds specifically to carry iron through your blood and deliver it to cells that need it. When your transferrin level is off, it can signal problems that routine blood counts miss entirely.

Your body adjusts how much transferrin it makes based on how much iron is available. When iron is scarce, the liver ramps up transferrin production to squeeze every bit of iron out of circulation. When iron is plentiful, or when the liver is damaged or inflamed, transferrin drops. That makes this single protein a surprisingly rich source of information about iron balance, liver health, and the presence of hidden inflammation.

How Transferrin Works

Transferrin is a protein produced almost entirely by your liver. Each transferrin molecule can grab up to two atoms of iron and ferry them to wherever your body needs them most, whether that is bone marrow (where red blood cells are made), muscle tissue, or the brain. This transport system also acts as a safety net: free-floating iron is chemically reactive and can damage cells, so binding it to transferrin keeps it from causing harm.

Your transferrin level rises when iron stores are low, as your body tries to capture and deliver as much iron as possible. It falls when iron is abundant, when your liver is struggling, or when widespread inflammation redirects the body's priorities. This dual sensitivity to iron status and liver function is what makes transferrin clinically useful, but it also means you need to interpret it alongside other markers rather than in isolation.

Transferrin and Liver Disease

Because the liver makes transferrin, a falling level can be an early signal that liver function is declining. In a study of 1,255 people with cirrhosis (scarring of the liver), those with transferrin below 180 mg/dL had dramatically worse survival rates. At five years, only about 31% of the low-transferrin group survived without needing a transplant, compared with 68% of those with transferrin at or above 180 mg/dL. This gap persisted even after accounting for other standard liver scores.

In severe alcoholic hepatitis (a sudden, life-threatening inflammation of the liver from heavy drinking), transferrin was the single best iron-related predictor of whether someone would survive to 28 days. It predicted short-term death about as well as complex composite scoring systems that require multiple lab values and clinical assessments. For anyone with known liver disease or heavy alcohol use, a low transferrin reading is a serious signal.

Heart Disease and Heart Failure

Iron deficiency is common in heart failure and worsens outcomes, but the way it shows up on labs can be confusing. A related measurement called transferrin saturation (TSAT), which shows how much of your transferrin is actually loaded with iron, has emerged as a strong predictor in heart disease. In a study of over 2,000 heart failure patients, those with low TSAT had significantly higher rates of death and heart failure hospitalizations, while ferritin levels showed no significant association with these outcomes.

In people with coronary artery disease, the relationship between TSAT and death follows a U-shape: risk is highest when TSAT drops below about 20% and also rises when it climbs above roughly 30%. The sweet spot for the lowest mortality risk appears to be a TSAT of 20 to 30%. Systemic inflammation partially explains the link between very low TSAT and death, meaning that low iron availability and active inflammation often travel together.

Cancer and Chronic Illness

In people with cancer-related muscle wasting (cachexia), low transferrin independently predicted shorter survival. Among 1,303 cachectic cancer patients followed for a median of about 20 months, those with low transferrin had roughly 50% higher risk of death compared to those with higher levels, even after adjusting for tumor type, stage, body weight, and inflammation.

In ovarian cancer specifically, low transferrin and a shift toward the iron-free form of the protein (called apo-transferrin) have been identified as markers of functional iron deficiency, a state where the body has iron locked away in storage but cannot mobilize it effectively. This pattern may help flag the disease and its nutritional impact earlier than standard markers alone.

Iron Overload and High Transferrin Saturation

While most clinical attention focuses on low transferrin or low TSAT, very high TSAT is also dangerous. In 718 patients with myelodysplastic syndromes (a group of blood cancers), TSAT above 80% predicted worse overall survival, even after adjusting for disease severity, age, and transfusion burden. In hereditary hemochromatosis (a genetic condition that causes excessive iron absorption), prolonged exposure to TSAT above 50% was linked to about four times the odds of worsening joint symptoms and about three times the odds of decreased work ability.

This is not a "higher is better" or "lower is better" marker in a simple sense. Instead, transferrin and its saturation level together describe how your iron transport system is functioning. Both extremes signal problems: too little iron reaching cells (low TSAT) or too much free iron overwhelming the system (very high TSAT).

Reference Ranges

These ranges are drawn from published biochemistry references and population studies. Your lab may report slightly different cutpoints depending on the testing method used. Sex-specific ranges may apply: studies in Saudi and Kenyan adult populations found that transferrin required sex-based partitioning for accurate interpretation. Compare your results within the same lab over time for the most meaningful trends.

A clinically important prognostic cutpoint from cirrhosis research is 180 mg/dL: patients below this threshold had markedly worse transplant-free survival. In children aged 3 to 15, reference ranges run approximately 223 to 356 mg/dL (converted from g/L), with values shifting by age and body weight.

When Results Can Be Misleading

Transferrin is what scientists call a negative acute-phase reactant, meaning your level drops during any significant inflammation, infection, or illness. If you draw blood while fighting a cold, recovering from surgery, or dealing with any acute inflammatory condition, your transferrin will read lower than your true baseline. Wait at least two to three weeks after recovering from acute illness before testing.

• Inflammation and infection: Any active infection, autoimmune flare, or recent surgery will suppress transferrin, potentially masking iron deficiency or mimicking liver disease. Ordering hs-CRP (high-sensitivity C-reactive protein) alongside transferrin helps distinguish real liver or iron problems from inflammation-driven drops.
• Liver disease: Since the liver makes transferrin, significant liver damage lowers the reading for reasons unrelated to iron status. A low transferrin in someone with known cirrhosis reflects liver function, not necessarily iron balance.
• Estrogen exposure: Oral contraceptives, hormone replacement therapy, and pregnancy can raise transferrin levels independently of iron status, potentially masking iron overload or making iron stores appear lower than they are.
• Protein malnutrition or nephrotic syndrome (a kidney condition that causes heavy protein loss in urine): Severe protein deficiency or heavy urinary protein loss lowers transferrin by reducing the raw materials the liver needs to produce it.

Tracking Your Trend

A single transferrin reading is a snapshot, not a verdict. Within-person biological variation for transferrin runs around 2.5 to 6%, depending on the study. That means a true change of roughly 15 to 20% between two readings is needed before you can be confident the difference is real rather than normal fluctuation. Lab-to-lab variation adds another layer of noise, so always compare results from the same laboratory.

Get a baseline reading when you are feeling well and free from acute illness. If you are making dietary changes, starting iron supplementation, or addressing a newly discovered deficiency, retest in three to four months to see whether the intervention is actually shifting your number. After that, annual monitoring is a reasonable cadence for most people. If you have liver disease, heart failure, chronic kidney disease, or an iron-loading condition, your physician may recommend testing every three to six months.

Tracking transferrin over time is especially valuable because its trajectory tells a different story than a single value. A gradually declining transferrin in someone without obvious iron overload may signal worsening liver function or chronic inflammation building quietly. A rising transferrin in someone on iron therapy could mean iron stores are becoming depleted faster than expected, rather than improving.